BioSpace reviews whose wallets got thicker in the biopharma industry, from largest to smallest, during the Nov. 11-17 period

San Francisco-based Olema Oncology secured $54 million in an oversubscribed Series B financing round to support the development of the company’s lead breast cancer treatment as well as expand ongoing research and development programs.

Morphic Therapeutic has completed a $80 million Series B financing to fund the biotechnology company’s two lead programs through clinical proof of concept, and to advance multiple other programs into the clinic.

ReViral announced the completion of a Series B financing worth $55 million, jointly led by New Leaf Venture Partners and Novo Ventures, with new investors Perceptive Advisors.

April 20, 2016By Mark Terry, Breaking News Staff   South San Francisco-based Second Genome announced today that it had closed on a Series B investment round with $42.6 million. It was co-led by Pfizer Venture Investments and Roche Venture Fund. They were joined by new investors, Digitalis Ventures, Adveq, LifeForce Capital, MBL Venture Capital, […]

April 19, 2016By Mark Terry, Breaking News Staff   DalCor Pharmaceuticals, which maintains offices in San Mateo, Calif., Switzerland, the UK and Montreal, Canada, announced today that it had wrapped up a private financing round valued at $150 million. Late in 2015, the company closed on a $50 million Series A round, and completed […]

SAN DIEGO, April 4, 2016 /PRNewswire/ — Human Longevity, Inc. (HLI), the genomics-based, technology-driven company, announced today that the company has completed an offering of Series B Preferred Stock, raising in excess of $220 million. HLI previously raised $80 million in its Series A offering which closed in Summer 2014. “The closing of our Series […]